Table 1.

TKI treatment of CP-CML patients.

Trial	Patient number (N)	Treatment	Efficacy	Reference
START-C	387 CP-CML Imatinib failure	Dasatinib 70 mg BID	CHR 90% CCyR 53% MMR 47%	7
START-R NCT00103844	150 CP-CML Imatinib failure	Dasatinib 70 mg BID	CHR 93% MCyR 53% CCyR 44%	8
CA180034 NCT00123474	622 CP-CML Imatinib failure	Dasatinib	100 mg QD CHR 92%, CCyR 50% 140 mg QD CHR 87%, CCyR 50% 70 mg BID CHR 88%, CCyR 53% 50 mg BID CHR 92%, CCyR 49%	9
NCT00109707	321 CP-CML Imatinib failure	Nilotinib 400 mg BID	CCyR 46% MMR 28%	10
NCT00261846	288 CP-CML Imatinib failure	Bosutinib 500 mg QD	CCyR 48% MMR 35%	11
DASISION NCT00481247	259 CP-CML 260 CP-CML	Dasatinib 100 mg QD Imatinib 400 mg QD	CCyR 86%, MMR 64% CCyR 82%, MMR 46%	12
DASCERN NCT01593254	174 CP-CML Suboptimal response to imatinib	Dasatinib 100 mg QD	MMR 64%	13
ENESTnd NCT00471497	846 CP-CML	Nilotinib Imatinib	Nilotinib 300 mg BID CCyR 80% Nilotinib 400 mg BID CCyR 78% Imatinib 400 mg QD CCyR 64%	14
MDACC	93 CP-CML	Dasatinib 100 mg QD 50 mg BID	CHR 98% CCyR 95% MMR 87%	15
S0325 NCT00070499	246 CP-CML	Dasatinib 100 mg Imatinib 400 mg	CHR 81%, CCyR 84%, MMR 59% CHR 82%, CCyR 69%, MMR 44%	16
BFORE NCT02130557	536 CP-CML	Bosutinib 400 mg QD Imatinib 400 mg QD	MMR 73.9%, CCyR 83.3% MMR 64.6%, CCyR 76.8%	17
BYOND trial NCT02228382	163 CP-CML Resistant or intolerant to prior TKIs	Bosutinib 500 mg QD	CCyR 80.6%, MMR 70.5%	18
PACE NCT01207440	267 CP-CML Dasatinib or nilotinib failure	Ponatinib 45 mg QD	MCyR 56%, MMR 34%, CCyR 46%	19
OPTIC NCT02467270	282 CP-CML Resistant to ≥1 prior TKI therapy	Ponatinib 45 mg QD 30 mg QD 15 mg QD	MCyR 50.5%, MMR 34.4% MCyR 33.3%, MMR 24.7% MCyR 43.8%, MMR 23.1%	20
ASCEMBL NCT03106779	233 CP-CML Resistant to ≥2 prior TKI therapy	Asciminib 40 mg BID Bosutinib 500 mg QD	MMR 25.5% MMR 13.2%	21

MMR, major molecular response; CHR, complete hematological response; MCyR, major cytogenetic response; CCyR, complete cytogenetic response.